View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
August 22, 2018updated 12 Jul 2022 1:12pm

MC2 reports positive top-line results from Phase lll psoriasis trial

MC2 Therapeutics has reported positive top-line results from a Phase lll trial to investigate the efficacy and safety of MC2-01 Cream compared to MC2-01 vehicle and Taclonex for the treatment of subjects with psoriasis vulgaris.

MC2 Therapeutics has reported positive top-line results from a Phase lll trial to investigate the efficacy and safety of MC2 -01 Cream compared to MC2 -01 vehicle and Taclonex for the treatment of subjects with psoriasis vulgaris.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The randomised, multicentre, investigator-blind, parallel-group trial included 796 patients at 55 dermatologists across the US.

During the trial, the patients applied trial medication topically once daily for eight weeks.

The trial’s primary goal was to demonstrate therapeutic non-inferiority of MC2 -01 Cream to the active comparator, as well as characterise the safety of MC2 -01 Cream in the psoriasis vulgaris patients.

Its primary efficacy endpoint included the proportion of subjects in each treatment group with ‘treatment success’ at week eight, defined as a minimum two-point decrease from baseline in physician global assessment (PGA) score.

The top-line results showed that the trial met its primary goal.

It was also found that MC2 -01 Cream offered a 60.2% reduction in itch at week four as measured by the frequency of a four-grade or greater improvement on an 11-point numeric rating scale of itch severity.

“The significant improvements in both treatment success and patient reported treatment convenience are particularly encouraging.”

The trial reported adverse events that were predictable pharmacological class effects typically associated with calcipotriene and topical corticosteroids.

In addition, the safety profile of MC2 -01 cream was found to be similar to that of Taclonex.

The trial lead investigator Linda Stein Gold said: “The significant improvements in both treatment success and patient reported treatment convenience are particularly encouraging.

“Enhanced patient satisfaction enabled by the MC2 -01 Cream PAD formulation may increase treatment compliance among patients, and positively impact real-life treatment outcomes even further.

“As such, PAD Technology holds the promise of redefining topicals.”

Psoriasis is a lifelong condition that considerably impacts patients’ quality of life.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena